07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Human induced pluripotent stem (iPS) cell-derived models of gliomagenesis for drug screening

Disease models TECHNOLOGY: Cell models Genetically engineered human iPS cell-derived models of gliomagenesis could be used to screen therapies for brain cancer. The cell models were generated from two sets of human iPS cells by a three-step...
07:00 , Apr 28, 2014 |  BioCentury  |  Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
08:00 , Mar 7, 2013 |  BC Innovations  |  Targets & Mechanisms

ALL emerges from relapse

Separate teams led by researchers from New York University and Columbia University have identified mutations in 5ʹ-nucleotidase cytosolic II that predict relapse, drug resistance and poor prognosis in acute lymphoblastic leukemia.1,2 Inhibiting the enzyme could...
08:00 , Feb 14, 2011 |  BioCentury  |  Regulation

Decelerated approval

After years of hints, complaints and informal discussion, FDA has explicitly asked its Oncologic Drugs Advisory Committee - and ODAC has agreed - to raise the hurdle cancer drugs will have to clear in order...
01:37 , Jan 7, 2011 |  BC Extra  |  Politics & Policy

ODAC to discuss accelerated approval requirements

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss ways to improve postmarketing trials required to confirm the benefit of drugs that received accelerated approval. The committee will review the status of...
08:00 , Nov 15, 2010 |  BioCentury  |  Strategy

Innovators pick China

Five years after he co-founded BioDuro LLC, a contract research organization operating in China, John Oyler is at it again. But this time, his new team is doing what would have been almost unthinkable in...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

Genmab, GlaxoSmithKline deal

Genmab declined to exercise its option to co-promote Arzerra ofatumumab, Bexar tositumomab and Arranon/ Atriance nelarabine in exchange for a $4.5 million payment from GlaxoSmithKline that will be triggered by FDA's acceptance of...
07:00 , Sep 24, 2007 |  BioCentury  |  Strategy

Asset accumulation

Asset accumulation Product Target Indication Status Atriance nelarabine (A) DNA synthesis Lymphoblastic leukemias Mkt (Nordic rights) Bexxar tositumomab (A) CD20 Non-Hodgkin's lymphoma (NHL) Mkt (U.S. rights) HuMax-CD4 zanolimumab CD4 Cutaneous T cell lymphoma (CTCL) Ph...
07:00 , Sep 24, 2007 |  BioCentury  |  Strategy

Genmab's commercial stockpile

Since the start of the year, Genmab A/S has been mulling whether to exercise an option under a 2006 deal with GlaxoSmithKline plc to co-promote cancer antibody HuMax-CD20 ofatumumab. Recent developments in two other alliances...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Company News

GlaxoSmithKline sales and marketing update

GSK said it does not expect to generate a profit from sales of Atriance nelarabine in Europe. The company did not disclose what the European price will be but did say that in the...